Sharps Technology (STSS) was once a tiny medical-syringe maker, but it now bills itself as a “leading publicly listed Solana treasury.” The company has now openly adopted what it calls a “digital asset treasury strategy focused on accumulating SOL” (the Solana (SOLUSD) token). In early September, Sharps announced it had “acquired over 2 million SOL,” roughly $400 million worth at prevailing prices. In other words, its balance sheet is now dominated by crypto rather than syringes. The company’s SEC filings and press releases trumpet Solana as “the fastest and most used blockchain in the world” and say Sharps is staking its coins to earn yield. This radical pivot has made STSS effectively a crypto proxy stock.
That shift means the company’s balance sheet is now dominated by crypto holdings rather than syringes. In filings and press releases, management describes Solana as “the fastest and most used blockchain in the world” and emphasizes that Sharps is staking its tokens to generate additional yield.
